May. 12 at 9:29 PM
$EDSA The conference presentation is largely irrelevant unless they are planning to present additional analyses or accompany it with a full peer reviewed data set including raw counts; no whisper on either. All that really matters now to maintain this valuation is whether Canadian regulators see enough to conditionally approve paridiprubart , how much additional grant funding they can muster, and what a registrational P3 would look like and how it's going to get funded. Rather that or essentially the same outcomes but with a BP partner. At close to a 250m fully diluted valuation you are priced for beyond perfection here.
I remain steadfast in my recent comment; the lack of dilution or updated shelf if by far the biggest bullish signal.
